The Certified Methadone Advocate Course

Saturday, October 16, 2004 Preconference Events

Frederick W. Christie, MA

AFIRM

Long Island, New York
H. Westley Clark, MD, JD, MPH

CSAT

Rockville, MD
Stewart Leavitt, PHD

Addiction Treatment Forum

Glenview, IL
James P. Connolly, CMA

PA NAMA

Newtown, PA
Herman Joseph, PHD, CMA

NAMA

New York, NY
J. Thomas Payte, MD, CMA

Colonial Management Group

Orlando, FL
Walter Ginter, CMA

NAMA

Westport, CT
Thomas Kresina

NIDA/CSAT

Rockville, MD
Joycelyn Woods, MA, CMA

NAMA

New York, NY

It is the view of the National Alliance of Methafdone Advocates (NAMA) that everyone who supports the use of methadone treatment is a potential methadone advocate. We encourage all supporters of methadone treatment, patients and non-patient, to become Certified Methadone Advocates (CMAs) so that all the energies directed toward the advancement of methadone tratment produce positive results.

This course fulfills the training requirement for Certification as a Methadone Advocate. It is designed for non-clinicians and involves 8 hours of rigorius training. The course equips participants with the tools they will nedd to succeed in the strugle to have methadone maintenance treatment universally acceptied as the “gold standard” for addiction treatment.

With these goals in mind the course presetation is as follows:

  • Addiction and Methadone – scientifically accurate yet in language understandable to the non-clinician.
  • Regulation and Accreditation – explained by experts from the Center for Substance Abuse Treatment (CSAT) who understand the systemic complexities.
  • Methadone Mythology – exposing the myths surrounding methadone treatment.
  • The Certified Methadone Advocate (CMA) – the mechanism of certification and how it will professionalize those committed to advocacy, includes advocacy on the Net and Methadone Anonymous.
  • Methadone Stigma – a history of administrative and community prejudice directed at methadone patients, plus analyses of possible solutions.
  • Office-Based Treatment Model – whether buprenorphrine or methadone, an advance for patients and an administrative hurdle for implementation.
  • Hepatitis C – the second most important subject for all methadone patients.

Sponsored by the National Alliance of Methadone Advocates.

Supported by the National Institute on Drug Abuse, Substance Abuse and Mental Health Services Administration, Center for Substance Abuse Treatment and Mallinckrodt, Inc.

Similar Posts

  • Honorary Patients

    Admin 08/25/2021

    The National Alliance of Methadone Advocates had never given an award or recognized anyone prior to 2003. This was because NAMA had decided that until methadone treatment was delivered with dignity and respect that those providing the treatment should not be given any acknowledgement. The few professionals who supported NAMA were asked to sit on…

  • NAMA Affiliates Pages

    Admin 10/23/2022

    Affiliates Package The first 2 parts of the Affiliates Package are in Ebook format. This means that your computer sees the file as an application and it will have an “exe” file extension. If you click on the file like it is an application – the Ebook with the documents will open. You can then…

  • Patient Support Community and Education Project Meeting

    Admin 05/03/2022

    Sunday, October 17, 2004 Special Meeting In September 2000, the Center for Substance Abuse Treatment brought together the leading national patient support and education organizations for a 2 day meeting to discuss the escalation of opioid dependency and the stigma associated with its related medication assisted treatments. Through this effort, the Methadone Patient Support and…

  • |

    OBOT Publications

    Admin 04/20/2023

    Publications Office Based Opioid Treatment Federal Code U.S. Federal Code. Confidentiality of Alcohol and Drug Abuse Patient Records. U.S. Federal Code. Medical Privacy HIPPA, National Standards to Protect the Privacy of Personal Health Information. Public Law 106-310, 106th Congress Sec. 3502. Controlled Substances Act, October 17, 2000. Physician Waiver to Prescribe, Dispense Schedule III-V Narcotic Drugs in the…